Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers / / Veysel Kayser.
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each p...
Saved in:
| VerfasserIn: | |
|---|---|
| Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 online resource (298 pages) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 01667nam a2200301 i 4500 | ||
|---|---|---|---|
| 001 | 993562207304498 | ||
| 005 | 20230225095127.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 230225s2022 sz o u000 0 eng d | ||
| 035 | |a (CKB)4920000001372291 | ||
| 035 | |a (NjHacI)994920000001372291 | ||
| 035 | |a (EXLCZ)994920000001372291 | ||
| 040 | |a NjHacI |b eng |e rda |c NjHacl | ||
| 041 | 1 | |a eng | |
| 050 | 4 | |a RM282.M65 |b .K397 2022 | |
| 082 | 0 | 4 | |a 615.37 |2 23 |
| 100 | 1 | |a Kayser, Veysel, |e author. | |
| 245 | 1 | 0 | |a Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers / |c Veysel Kayser. |
| 264 | 1 | |a Basel : |b MDPI - Multidisciplinary Digital Publishing Institute, |c 2022. | |
| 300 | |a 1 online resource (298 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | |a Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed February 24, 2023). | ||
| 520 | |a The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Monoclonal antibodies |x Therapeutic use. | |
| 776 | |z 3-0365-2686-2 | ||
| 906 | |a BOOK | ||
| ADM | |b 2023-03-01 01:51:16 Europe/Vienna |f system |c marc21 |a 2022-09-22 08:09:39 Europe/Vienna |g false | ||
| AVE | |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338132750004498&Force_direct=true |Z 5338132750004498 |8 5338132750004498 | ||